The global sickle cell anemia testing & screening market size was valued at USD 261.16 Million in 2022 and is projected to reach USD 419.25 Million by 2031, expanding at a CAGR of 5.4% during the forecast period, 2023–2031. Hemoglobinopathies include a category of inherited disorders, including sickle cell disease (SCD) that occurs due to defective hemoglobin damaging and deforming RBCs.
The sickle cell disease affects millions of people across the globe and is common in the western hemisphere, Saudi Arabia, India, and countries in Sub-Saharan Africa and the Mediterranean region. The early detection of sickle cell anemia is essential for patient, as the medication for this condition is not easilyavailable and accessible.
Sickle Cell Anemia Testing & Screening Market Trends, Drivers, Restraints, and Opportunities
- Several government programs to promote the diagnosis of sickle cell anemia are projected to drivethe demand for sickle cell anemia testing & screening.
- The implementation of newborn screening programs in sickle cell anemia affected areas such as Ghana, Kenya, and Democratic Republic of the Congo (DRC) is expected to fuel the market growth during the forecast period.
- The development of hand-held, non-invasive digital devices for the identification of sickle cell disease is intended to create hindrances in the market.
- Key market players concentrate on developing point-of-care tests using methods such as densitometry, microfluid electrophoresis, lateral flow immunoassay, and others that are accessible, compact, specific, and highly sensitive. Hence, this creates opportunities for the market.
Scope of Sickle Cell Anemia Testing & Screening Market Report
The report on the global sickle cell anemia testing & screening market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Sickle Cell Anemia Testing & Screening Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016 – 2021
|
|
Forecast Period
|
2023 – 2031
|
|
Segmentation
|
Technologies (Hemoglobin Electrophoresis[Isoelectric Focusing and Others], High-performance Liquid Chromatography (HPLC), Point-of-Care Tests [Lateral Flow Immunoassay, Paper-based Rapid Diagnostics, and Others] and Other Tests), Age Groups (Newborn Screening (12 months and Below), Adult Screening (25 years to 60 years), and Other Age Groups (1 year to 25 years and Above 60 years)), Sector Types (Government Labs, Private Labs, Corporate Labs, and Public-Private-Partnerships (PPP))
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
STRECK, INC., Daktari Diagnostics, BIOMEDOMICS INC., Laboratory Corporation of America Holdings, Request A Test, Ltd., HALCYON BIOMEDICAL INCORPORATED, Silver Lake Research Corporation, HEMOTYPE, HEMEX HEALTH, Bio-Rad Laboratories, Inc., PerkinElmer Inc., and Quest Diagnostics
|
Sickle Cell Anemia Testing & Screening Market Segment Insights
Technologies Segment Analysis
In the terms of technologies, the sickle cell anemia testing & screening market can be segmented into hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), point-of-care tests, and other tests. The hemoglobin electrophoresis segment is divided into isoelectric focusing and others.
The point-of-care tests segment is further categorized as lateral flow immunoassay, paper-based rapid diagnostics, and others. The hemoglobin electrophoresis segment held a significant share of the market in 2019.
The point-of-care technology segment is expected to grow at a high pace during the forecast period. Substantial developments in smartphone-based and paper-based assays are boosting the growth of the point-of-care tests segment.
Age Group Segment Analysis
Based on age group, the sickle cell anemia testing & screening market is fragmented into newborn screening (12 months and below), adult screening (25years to 60 years), and other age groups (1 year to 25 years and above 60 years). The newborn screening segment held considerable market share in 2019.
The adult screening segment is expected to expand at the significant CAGR during the forecast period. SCD diagnosis and management vary at various levels, depending on the age of the patient. These variations in SCD diagnosis and management are owing disparities in SCD-associated pain, co-morbidity, and psychosocial effects with respect to the age range of patients with sickle cell anemia.
Sector Types Segment Analysis
On the basis of scetor types, the market can be segregated into government labs, private labs, corporate labs, and public-private-partnerships (PPP). The government laboratories segment is expected to hold significant market share due to increasing developments in government laboratories. The PPP segment is expected to expand at a considerable CAGR owing to increasing investments in PPP during the forecast period.
Regional Analysis
In terms of regions, the global sickle cell anemia testing & screening market is split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America constituted a considerable share of the global market in 2019.
Newborn screening programs are introduced in all 50 states of the US and 8 provinces of Canada, providing a favorable environment for organizations participating in the market.
Segments
Technologies
- Hemoglobin Electrophoresis
- Isoelectric Focusing
- Others
- High-performance Liquid Chromatography (HPLC)
- Point-of-Care Tests
- Lateral Flow Immunoassay
- Paper-Based Rapid Diagnostics
- Others
- Other Tests
Age Groups
- Newborn Screening (12 Months and Below)
- Adult Screening (25 Years to 60 Years)
- Other Age Groups (1 Year to 25 Years & Above 60 Years)
Sector Types
- Government Labs
- Private Labs
- Corporate Labs
- Public-Private-Partnerships (PPP)
Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
Key Players
Competitive Landscape
Key players in the sickle cell anemia testing & screening market include STRECK, INC., Daktari Diagnostics, BIOMEDOMICS INC., Laboratory Corporation of America Holdings, Request A Test, Ltd., HALCYON BIOMEDICAL INCORPORATED, Silver Lake Research Corporation, HEMOTYPE, HEMEX HEALTH, Bio-Rad Laboratories, Inc., PerkinElmer Inc., and Quest Diagnostics.
Mergers & acquisitions, collaborations, agreements, and partnerships are some growth strategies adopted by these players to strengthen their geographical presence.
Request For Customization
Enquiry Before Buying
Speak With Analyst
